Boehringer Ingelheim to close North American sites
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim is to close its virology research facility in Laval, Quebec (Canada) and reduce its API production capacity in Petersburg, Virginia (US). The German-headquartered private company's cuts will affect 250-270 people in total.